AG-013736 API Replacement: Trace Metal & Solvent Residue Limits
Cross-Coupling Catalyst Carryover: How Residual Pd/Cu Drives Axitinib Downstream Color Shifts & Batch Failures
Axitinib synthesis relies heavily on palladium-catalyzed cross-coupling reactions to construct the pyrazole-benzimidazole scaffold. While standard purification protocols aim to remove these catalysts, trace residues of palladium (Pd) and copper (Cu) can persist in adsorption sites or within crystal lattice defects. From a field engineering perspective, the critical risk is not merely the presence of these metals, but their catalytic activity during storage. We have documented cases where residual Pd, even when below standard detection thresholds, drives the oxidation of the pyrazole moiety under elevated humidity conditions. This results in a non-linear color shift, often manifesting as a progressive yellowing that accelerates after the third month of accelerated stability testing. This behavior is distinct from photodegradation and indicates that catalyst removal efficiency must be validated through long-term stability indicators, not just initial assay results. Procurement managers must ensure that the supplier's workup includes robust chelation steps to mitigate this edge-case degradation pathway.
Exact ICH Q3D Limits vs. 0.06% Residue on Ignition: Validating Axitinib Purity Grades & COA Traceability
Residue on Ignition (ROI) is a gravimetric measure of inorganic residue, often specified at a benchmark of 0.06% for bulk API quality. However, ROI cannot differentiate between benign inorganic salts and toxic heavy metals. A batch may pass the 0.06% ROI limit while containing localized concentrations of palladium or copper that exceed ICH Q3D thresholds. For the AG-013736 equivalent, we validate against ICH Q3D Class 1 limits for all relevant elements. The table below outlines the critical parameters. Note that specific purity values and elemental impurity concentrations are batch-dependent and must be verified via the batch-specific COA.
| Parameter | Specification / Benchmark | Notes |
|---|---|---|
| Residue on Ignition | ≤ 0.06% | Sulfated ash method |
| Purity | Please refer to the batch-specific COA | HPLC assay |
| Polymorphic Form | Form A / Form B | Verified by XRPD |
| Elemental Impurities (Pd/Cu) | Please refer to the batch-specific COA | ICP-MS per ICH Q3D |
| Solvent Residues | Please refer to the batch-specific COA | GC per ICH Q3C |
DMF versus EtOAc Solvent Residue Profiles: Impact on Axitinib Tablet Compression & Dissolution Rates
Solvent choice in API manufacturing directly impacts downstream Oral Solid Dosage (OSD) processing. Dimethylformamide (DMF) is a Class 2 solvent that can act as a plasticizer for common binders such as HPMC and PVP. Residual DMF can reduce tablet hardness, increase friability, and alter dissolution profiles by affecting the wetting properties of the granules. In field trials, we have observed that elevated DMF levels can lead to capping during high-speed compression due to binder softening. Ethyl acetate (EtOAc), a Class 3 solvent, is more volatile and poses less risk to mechanical properties, but requires efficient removal to meet ICH Q3C limits. Our process controls solvent profiles to ensure no impact on tablet compression or dissolution rates, providing a reliable formulation guide for R&D teams.
Drop-in Replacement for AG-013736 API: Technical Specs, Bulk Packaging Configurations & Procurement-Ready COA Parameters
Ningbo Inno Pharmchem provides a drop-in replacement for AG-013736 API, delivering identical technical parameters and performance benchmarks for oncology API applications. As a global manufacturer of pharmaceutical grade intermediates, we focus on supply chain reliability and cost-efficiency without compromising quality. Our axitinib drop-in replacement specifications align with major pharmacopeial standards, ensuring seamless integration into existing formulations. Bulk packaging configurations include 25kg double-lined drums and 200kg IBCs, optimized for secure freight transport. For detailed technical data, please review our axitinib drop-in replacement specifications. We provide comprehensive COAs with full traceability for every batch.
Frequently Asked Questions
How do I verify heavy metal limits in the COA?
Verification requires reviewing ICP-MS data for specific elements such as palladium and copper against ICH Q3D Class 1 limits. The COA must list individual elemental impurities rather than relying solely on Residue on Ignition, as ROI cannot distinguish between benign salts and toxic metals. Ensure the analytical method is validated for the specific matrix and that detection limits are sufficiently low to confirm compliance.
Why do residual solvent profiles matter for OSD processing?
Residual solvents can significantly impact tablet compression and dissolution rates. Class 2 solvents like DMF can plasticize binders, reducing hardness and increasing friability, while also altering granule wetting. Class 3 solvents like EtOAc are less risky but must be controlled to meet regulatory limits. Understanding the solvent profile allows formulators to predict mechanical behavior and ensure consistent dissolution performance.
Sourcing and Technical Support
Ningbo Inno Pharmchem supports your formulation needs with reliable supply and technical expertise. Our team provides detailed COAs and stability data to assist in your validation processes. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.